Detlef Klaus Bartsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Detlef Klaus Bartsch has a total of 488 co-authors. Here are the top co-authors by number of shared publications:
- Elisabeth Maurer
Department of Visceral‐, Thoracic‐ and Vascular Surgery Philipps‐University Marburg Marburg Germany
9 shared publications - Pietro Di Fazio
Department of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Marburg, Germany
8 shared publications - Jerena Manoharan
Klinik für Viszeral‑, Thorax- und Gefäßchirurgie, Philipps-Universität Marburg, Marburg, Deutschland
7 shared publications - Peter Langer
Institute of Chemistry University of Rostock Rostock Germany
6 shared publications - Moritz Jesinghaus
Institute of Pathology, Philipps-Universität Marburg, Marburg, Germany
5 shared publications Peter Langer
Klinikum Hanau GmbH, Dept Gen Visceral & Thorac Surg, Hanau, Germany
5 shared publications
Latest Publications
- 24 August 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (9) , 697-698
Seltene neuroendokrine Neoplasien des Gastrointestinaltraktes
- 24 August 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (9) , 697-698
Seltene neuroendokrine Neoplasien des Gastrointestinaltraktes
- 8 July 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (9) , 749-750
Lobektomie versus totale Thyreoidektomie beim papillären Schilddrüsenkarzinom mit intermediärem Risiko
- 8 July 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (9) , 749-750
Lobektomie versus totale Thyreoidektomie beim papillären Schilddrüsenkarzinom mit intermediärem Risiko
- Open Access
- 4 July 2026
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2026 (7)
Implementation of transoral robotic thyroid surgery in a European tertiary center
Transoral thyroidectomy via vestibular approach has gained increasing acceptance due to its excellent cosmetic outcomes. Transoral robotic thyroidectomy (TORT) represents a further technical evolution, potentially offering enhanced options of instrument movement and visualization. However, no reports from Europe were yet published. We report the first TORT performed in Germany in a 56-year-old female presenting with a symptomatic 20 × 16 mm sized nodule in the right thyroid lobe measuring 14 ml. A right hemithyroidectomy was performed using TORT with the daVinci Xi® robotic system. Total operative time was 230 min. The postoperative course was uneventful, and the patient was discharged on postoperative day 3. TORT is feasible and safe in selected patients also in the German hospital setting, although the additional costs are not reimbursed by the German health system. This case demonstrates the technical applicability and highlights key procedural steps for implementation.
- 4 July 2026
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2026 (7)
Open AccessImplementation of transoral robotic thyroid surgery in a European tertiary center
Transoral thyroidectomy via vestibular approach has gained increasing acceptance due to its excellent cosmetic outcomes. Transoral robotic thyroidectomy (TORT) represents a further technical evolution, potentially offering enhanced options of instrument movement and visualization. However, no reports from Europe were yet published. We report the first TORT performed in Germany in a 56-year-old female presenting with a symptomatic 20 × 16 mm sized nodule in the right thyroid lobe measuring 14 ml. A right hemithyroidectomy was performed using TORT with the daVinci Xi® robotic system. Total operative time was 230 min. The postoperative course was uneventful, and the patient was discharged on postoperative day 3. TORT is feasible and safe in selected patients also in the German hospital setting, although the additional costs are not reimbursed by the German health system. This case demonstrates the technical applicability and highlights key procedural steps for implementation.
- Open Access
- 23 June 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (7) , e70219
Characteristics, management, and outcomes of patients with VIPoma –A retrospective analysis of the ENETS database
Introduction: VIPoma is an extremely rare functioning pancreatic neuroendocrine tumor. Therefore, data regarding treatment and outcome are very limited. Aim (s): This multicenter study aimed to analyze clinical characteristics, real‐world management, and outcomes of patients with VIPoma. Methods: Patients with VIPoma treated in a 20‐year period at 14 referral centers for neuroendocrine tumors (NET) were collected in the ENETS Database. Clinical characteristics, therapeutic interventions, and outcomes were analyzed retrospectively. Disease‐free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Results: Of 70 patients, 59 (54% male) with a median age of 55 years were included. Forty‐six (78%) patients were diagnosed due to the classical watery diarrhea–hypokalemia–achlorhydria (WDHA) syndrome, and 40 (68%) presented with distant metastases at diagnosis. Fifty‐two (88%) had serum VIP levels >2 times the upper normal limit and the median Ki‐67 index was 5% (range 1%–40%). Surgery of the primary VIPoma was performed in 32 (54%), with curative intent in 22 (37%). In patients with stage I–III disease ( n = 19), long‐term cure was achieved in only 26% (5/19), with a median DFS of 81 (95%‐CI: 1–215) months and 10‐year OS of 78% (95%‐CI: 61%–100%). In stage IV patients ( n = 53, 40 at diagnosis, 13 disease progression), the sequence and type of 354 treatment lines varied, while SSA ( n = 77, 22%), loco‐regional liver‐directed therapy ( n = 72, 20%), and chemotherapy ( n = 69, 19%) were most often applied. Median OS for patients with stage IV at diagnosis was 142 (95%‐CI: 87–not available (NA)) months with 10‐year survival of 50% (95%‐CI: 35%–73%). Conclusion: Patients with VIPoma treated at NET centers have relatively favorable survival, even with distant metastases at diagnosis, although long‐term cure rates remain low.
- 23 June 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (7) , e70219
Open AccessCharacteristics, management, and outcomes of patients with VIPoma –A retrospective analysis of the ENETS database
Introduction: VIPoma is an extremely rare functioning pancreatic neuroendocrine tumor. Therefore, data regarding treatment and outcome are very limited. Aim (s): This multicenter study aimed to analyze clinical characteristics, real‐world management, and outcomes of patients with VIPoma. Methods: Patients with VIPoma treated in a 20‐year period at 14 referral centers for neuroendocrine tumors (NET) were collected in the ENETS Database. Clinical characteristics, therapeutic interventions, and outcomes were analyzed retrospectively. Disease‐free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method. Results: Of 70 patients, 59 (54% male) with a median age of 55 years were included. Forty‐six (78%) patients were diagnosed due to the classical watery diarrhea–hypokalemia–achlorhydria (WDHA) syndrome, and 40 (68%) presented with distant metastases at diagnosis. Fifty‐two (88%) had serum VIP levels >2 times the upper normal limit and the median Ki‐67 index was 5% (range 1%–40%). Surgery of the primary VIPoma was performed in 32 (54%), with curative intent in 22 (37%). In patients with stage I–III disease ( n = 19), long‐term cure was achieved in only 26% (5/19), with a median DFS of 81 (95%‐CI: 1–215) months and 10‐year OS of 78% (95%‐CI: 61%–100%). In stage IV patients ( n = 53, 40 at diagnosis, 13 disease progression), the sequence and type of 354 treatment lines varied, while SSA ( n = 77, 22%), loco‐regional liver‐directed therapy ( n = 72, 20%), and chemotherapy ( n = 69, 19%) were most often applied. Median OS for patients with stage IV at diagnosis was 142 (95%‐CI: 87–not available (NA)) months with 10‐year survival of 50% (95%‐CI: 35%–73%). Conclusion: Patients with VIPoma treated at NET centers have relatively favorable survival, even with distant metastases at diagnosis, although long‐term cure rates remain low.
- 9 June 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (9) , 726
OMW: Präsakraler neuroendokriner Tumor
- 9 June 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (9) , 726
OMW: Präsakraler neuroendokriner Tumor
- Open Access
- 14 May 2026
- Published by CERN in Open Research Europe
- Vol. 6, 168
Detection, identification and quantification of NGTs in EU authorization procedures – No solution without legislative change
For the purposes of GMO authorisation, applicants are required to submit validated methods for the detection, identification and quantification (DIQ). For classical transgenic organisms, this requirement has proven workable. For products derived from New Genomic Techniques (NGTs), specifically those introducing small insertions and deletions (InDels) without foreign genetic material, it has not. NGT-induced genomic changes are frequently indistinguishable from naturally occurring mutations, making identification legally required but technically unachievable with currently available analytical tools. This open letter examines whether recently proposed DIQ methodologies, including genomic fingerprinting approaches based on single nucleotide variant (SNV) profiling, can bridge this gap. We find that while such approaches advance detection capabilities, they fall short of the identification and quantification standards demanded by EU law, for reasons such as the absence of universal pangenome datasets, the complexity of polyploid crop genomes, the loss of fingerprint integrity through elite line crossing, and the dependence of recombination rates on multiple species-specific factors. The mismatch between legal requirements and scientific feasibility has consequences for authorisation procedures, supply chain compliance, organic farming integrity, and international trade. We conclude that no purely technical solution is forthcoming and that legislative change is necessary. Aligning the EU’s evidentiary standards with technical reality is a precondition for a functional and enforceable GMO authorisation system.
- 14 May 2026
- Published by CERN in Open Research Europe
- Vol. 6, 168
Open AccessDetection, identification and quantification of NGTs in EU authorization procedures – No solution without legislative change
For the purposes of GMO authorisation, applicants are required to submit validated methods for the detection, identification and quantification (DIQ). For classical transgenic organisms, this requirement has proven workable. For products derived from New Genomic Techniques (NGTs), specifically those introducing small insertions and deletions (InDels) without foreign genetic material, it has not. NGT-induced genomic changes are frequently indistinguishable from naturally occurring mutations, making identification legally required but technically unachievable with currently available analytical tools. This open letter examines whether recently proposed DIQ methodologies, including genomic fingerprinting approaches based on single nucleotide variant (SNV) profiling, can bridge this gap. We find that while such approaches advance detection capabilities, they fall short of the identification and quantification standards demanded by EU law, for reasons such as the absence of universal pangenome datasets, the complexity of polyploid crop genomes, the loss of fingerprint integrity through elite line crossing, and the dependence of recombination rates on multiple species-specific factors. The mismatch between legal requirements and scientific feasibility has consequences for authorisation procedures, supply chain compliance, organic farming integrity, and international trade. We conclude that no purely technical solution is forthcoming and that legislative change is necessary. Aligning the EU’s evidentiary standards with technical reality is a precondition for a functional and enforceable GMO authorisation system.
- 23 April 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (5) , 349-350
Aktuelle Diagnostik und Therapie der Nebennierentumoren
- 23 April 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (5) , 349-350
Aktuelle Diagnostik und Therapie der Nebennierentumoren
- Open Access
- 3 April 2026
- Published by Elsevier in Cancer Genetics
- Vol. 304-305, 103-113
Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline – relevance for additional therapeutic options
- 3 April 2026
- Published by Elsevier in Cancer Genetics
- Vol. 304-305, 103-113
Open AccessOptimized precision oncology through implementation of a comprehensive molecular analysis pipeline – relevance for additional therapeutic options
- Open Access
- 5 March 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (5) , 387
OMW: Inzidentalom der Nebenniere
- 5 March 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (5) , 387
Open AccessOMW: Inzidentalom der Nebenniere
- Open Access
- 2 February 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (5) , 365-372
Adrenokortikales Karzinom (ACC): aktuelle chirurgische Therapieprinzipien
Zusammenfassung Das adrenokortikale Karzinom (ACC) zählt zu den seltensten soliden Tumoren, weist aber eine ausgeprägte biologische Aggressivität und ein hohes Rezidivpotenzial auf. Die vollständige Tumorresektion (R0) stellt die einzige kurative Therapieoption dar und bestimmt maßgeblich das Langzeitüberleben. Aufgrund der funktionellen Heterogenität der Tumoren sowie der häufig bestehenden Kortisol- oder Androgenexzesse müssen präoperative Diagnostik und perioperative Betreuung in enger interdisziplinärer Zusammenarbeit erfolgen. Die offene Adrenalektomie gilt weiterhin als Goldstandard, während minimalinvasive Verfahren in streng selektionierten Fällen und in ausgewiesenen Hochvolumenzentren vertretbar sind. Die Bedeutung einer systematischen Lymphadenektomie nimmt zu, auch wenn deren optimales Ausmaß noch nicht abschließend definiert ist. Postoperativ richtet sich die adjuvante Therapie nach der individuellen Risikokonstellation. Mitotan ist in Fällen mit intermediärem und hohem Rezidivrisiko indiziert. Rezidive treten häufig auf und sollten, sofern technisch möglich, chirurgisch behandelt werden. In metastasierten Stadien stehen multimodale Konzepte im Vordergrund, die chirurgische, interventionell-radiologische und systemische Therapien kombinieren. Insgesamt bleibt die Prognose limitiert, allerdings stellen die chirurgische Expertise und die Behandlung in spezialisierten Zentren entscheidende Determinanten für eine verbesserte Prognose dar.
- 2 February 2026
- Published by Springer Nature in Die Chirurgie
- Vol. 97 (5) , 365-372
Open AccessAdrenokortikales Karzinom (ACC): aktuelle chirurgische Therapieprinzipien
Zusammenfassung Das adrenokortikale Karzinom (ACC) zählt zu den seltensten soliden Tumoren, weist aber eine ausgeprägte biologische Aggressivität und ein hohes Rezidivpotenzial auf. Die vollständige Tumorresektion (R0) stellt die einzige kurative Therapieoption dar und bestimmt maßgeblich das Langzeitüberleben. Aufgrund der funktionellen Heterogenität der Tumoren sowie der häufig bestehenden Kortisol- oder Androgenexzesse müssen präoperative Diagnostik und perioperative Betreuung in enger interdisziplinärer Zusammenarbeit erfolgen. Die offene Adrenalektomie gilt weiterhin als Goldstandard, während minimalinvasive Verfahren in streng selektionierten Fällen und in ausgewiesenen Hochvolumenzentren vertretbar sind. Die Bedeutung einer systematischen Lymphadenektomie nimmt zu, auch wenn deren optimales Ausmaß noch nicht abschließend definiert ist. Postoperativ richtet sich die adjuvante Therapie nach der individuellen Risikokonstellation. Mitotan ist in Fällen mit intermediärem und hohem Rezidivrisiko indiziert. Rezidive treten häufig auf und sollten, sofern technisch möglich, chirurgisch behandelt werden. In metastasierten Stadien stehen multimodale Konzepte im Vordergrund, die chirurgische, interventionell-radiologische und systemische Therapien kombinieren. Insgesamt bleibt die Prognose limitiert, allerdings stellen die chirurgische Expertise und die Behandlung in spezialisierten Zentren entscheidende Determinanten für eine verbesserte Prognose dar.